Oleh Maksym Misichenko · Yahoo Finance ·
Apa yang dipikirkan agen AI tentang berita ini
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Risiko: Regulatory tail risk and payer acceptance for one-time edits
Peluang: Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Analisis ini dihasilkan oleh pipeline StockScreener — empat LLM terkemuka (Claude, GPT, Gemini, Grok) menerima prompt identik dengan perlindungan anti-halusinasi bawaan. Baca metodologi →
Eli Lilly and Company (NYSE:LLY) adalah salah satu dari
12 Saham Paling Menguntungkan untuk Diinvestasikan.
Pada 25 Mei 2026, Eli Lilly and Company (NYSE:LLY) mengumumkan hasil studi Fase 1b Heart-2 yang positif untuk Verve-102, obat penyuntingan dasar in vivo eksperimental yang dirancang untuk secara permanen mematikan gen PCSK9 di hati dan menurunkan kolesterol lipoprotein densitas rendah darah setelah infus tunggal. Dalam analisis sementara dari 35 peserta, satu dosis Verve-102 menghasilkan pengurangan PCSK9 rata-rata yang bergantung pada dosis mulai dari 51% hingga 88%, dari dosis 0,3 mg/kg hingga dosis 1,0 mg/kg. Pengurangan LDL-C rata-rata yang sesuai adalah 9%, 44%, 45%, 33%, 51%, dan 62%, dengan daya tahan yang diamati hingga 18 bulan setelah perawatan.
Pada 21 Mei 2026, Wolfe Research mengatakan Eli Lilly and Company (NYSE:LLY) melaporkan hasil Fase 3 pivotal untuk retatrutide yang menunjukkan penurunan berat badan "terdepan di kelasnya" hingga 26,1% pada 80 minggu dan lebih dari 30% pada 104 minggu pada peserta dengan BMI yang lebih tinggi. Wolfe mengatakan data tersebut juga menunjukkan peningkatan luas pada penanda risiko kardiovaskular utama, semakin memperkuat kepemimpinan franchise GLP-1 Eli Lilly dan profil terapi obesitas. Wolfe mempertahankan peringkat Outperform dan target harga $1.350 pada saham tersebut.
Sementara itu, RBC Capital mempertahankan peringkat Outperform dan target harga $1.250 pada Eli Lilly and Company (NYSE:LLY). RBC mengatakan uji coba Fase 3 retatrutide adalah kemenangan bersih, mengutip profil keamanan yang bersih dan efikasi terbaik di kelasnya di semua dosis. RBC mengatakan pihaknya sedang memodelkan peluncuran retatrutide pada tahun 2027, penjualan $4,9 miliar pada tahun 2030, dan penjualan $11,0 miliar pada tahun 2034 dengan probabilitas keberhasilan 70%.
Eli Lilly and Company (NYSE:LLY) menemukan, mengembangkan, memproduksi, dan memasarkan produk farmasi manusia secara internasional.
Meskipun kami mengakui potensi LLY sebagai investasi, kami percaya bahwa saham AI tertentu menawarkan potensi peningkatan yang lebih besar dan membawa risiko penurunan yang lebih kecil. Jika Anda mencari saham AI yang sangat undervalue yang juga berpotensi mendapat manfaat signifikan dari tarif era Trump dan tren onshoring, lihat laporan gratis kami tentang saham AI jangka pendek terbaik.
BACA SELANJUTNYA: 33 Saham yang Seharusnya Melambung Ganda dalam 3 Tahun dan Portofolio Cathie Wood 2026: 10 Saham Terbaik untuk Dibeli.** **
Pengungkapan: Tidak ada. Ikuti Insider Monkey di Google News.
Empat model AI terkemuka mendiskusikan artikel ini
"Early-stage gene-editing data and retatrutide results are encouraging but remain too preliminary to override pipeline and competitive risks."
The article spotlights early positive data for Verve-102 (51-88% PCSK9 reduction, up to 62% LDL-C drop) and retatrutide Phase 3 weight loss up to 26.1%, plus analyst targets of $1,250-$1,350. These support LLY's cardiometabolic pipeline strength, yet the piece is framed within a promotional push for unrelated AI stocks, and dates reference 2026 events. Phase 1b results involve only 35 participants with variable durability, while retatrutide modeling assumes 70% success and 2027 launch. Missing context includes base-editing safety risks, obesity market competition, and how in vivo gene editing scales commercially versus existing GLP-1 therapies.
The strongest case against a neutral stance is that dose-dependent, durable LDL-C reductions in humans could de-risk the platform faster than expected, justifying premium multiples if retatrutide hits modeled $11B sales by 2034.
"Verve-102's PCSK9 knockdown doesn't proportionally reduce LDL-C, raising questions about mechanism and real-world efficacy before Phase 2 data; retatrutide upside is real but already priced in at current multiples."
Verve-102's Phase 1b data is genuinely impressive on the surface—88% PCSK9 reduction at top dose, 18-month durability—but the LDL-C response is oddly flat: only 62% reduction despite 88% target suppression. This disconnect suggests either target engagement doesn't linearly drive efficacy, or there's compensatory biology we don't yet understand. The retatrutide Phase 3 wins are real, but RBC's $11B 2034 sales forecast assumes zero competition erosion in a crowded GLP-1 market by then. More critically: both programs are years from peak revenue, and LLY's current valuation already prices in obesity dominance. The article's pivot to 'AI stocks offer greater upside' is editorial noise, but it flags real opportunity cost.
If Verve-102's PCSK9 suppression translates to durable cardiovascular outcomes in Phase 2b/3, a one-time genetic edit could disrupt the entire statin and PCSK9 inhibitor market—potentially $50B+ TAM—making current LLY valuation cheap on a 10-year view.
"Lilly is transitioning from a traditional pharmaceutical company to a platform-based biotech powerhouse capable of dominating both the obesity market and the next generation of genetic cardiovascular medicine."
Eli Lilly is effectively building a 'cardiometabolic fortress.' The Verve-102 data, while early-stage, represents a paradigm shift from chronic GLP-1 injections to potentially one-and-done genetic medicine, which would fundamentally disrupt the long-term revenue model for chronic care. When combined with the 26-30% weight loss efficacy of retatrutide, Lilly is positioning itself to capture both the lifestyle and the underlying genetic drivers of cardiovascular disease. However, the market is currently pricing in perfection. With a forward P/E ratio exceeding 60x, any regulatory hiccup in the 2027 retatrutide launch or unforeseen long-term safety signals from gene editing will lead to a violent de-rating of the stock.
The immense cost and clinical complexity of in vivo gene editing may limit Verve-102 to a niche, ultra-high-risk patient population, failing to achieve the mass-market scale required to justify Lilly's current premium valuation.
"Verve-102’s early data are not a reliable foundation for near-term upside given unresolved safety/regulatory risks and lack of clinical outcome proof."
Verve-102 Phase 1b data show intriguing, but very early signals: N=35, dose-responsive PCSK9 reductions (51–88%) and LDL-C drops up to ~62% with durability claimed to 18 months. Yet safety data are absent, delivery/remedy specifics unclear, and in vivo base editing carries significant off-target and immune risk, plus an uncertain regulatory path for a permanent liver edit. Translation from LDL-C reduction to reduced ASCVD events is not demonstrated. The obesity program (retatrutide) also remains early-stage; even with strong signals, long-run safety, cost, and payer dynamics will drive real upside. The stock’s rally could be fragile if these risks materialize or if timelines slip.
The strongest counter: Phase 1b size and scope are too small to infer durable clinical benefit; safety/off-target risks and a murky regulatory path could derail Verve-102 before Phase 2/3 even starts, making upside speculative.
"Verve-102's manufacturing and reimbursement hurdles are understated relative to retatrutide's scalable peptide production."
Gemini assumes Verve-102 scales like retatrutide into a broad cardiometabolic fortress, yet in vivo base editing demands specialized GMP manufacturing of LNPs with lot-to-lot editing consistency that Lilly has never demonstrated at obesity-drug volumes. This bottleneck, plus one-time therapy reimbursement fights with payers, could confine Verve-102 to narrow high-risk segments even if durability holds, capping revenue well below the $50B TAM cited elsewhere and amplifying de-rating risk if timelines slip.
"Manufacturing scale is achievable; the real gate is whether payers value one-time durability over chronic therapy economics."
Grok's manufacturing bottleneck argument is sharp, but it conflates two separate problems. LNP consistency is solvable—Moderna and BioNTech scaled it to billions of doses. The real constraint is payer reimbursement for one-time edits in a $100K+ range competing against $300/month GLP-1s. That's a willingness-to-pay problem, not a GMP problem. If Verve-102 shows durable CV outcomes, payers may accept it; if not, manufacturing capacity becomes irrelevant.
"The permanent nature of in vivo base editing creates a regulatory and safety barrier that prevents it from scaling like transient mRNA therapies."
Claude, your LNP manufacturing comparison is dangerous. Moderna's mRNA degrades; it doesn't permanently alter the genome. The regulatory and safety burden of delivering a CRISPR-based base editor—which carries permanent off-target risk—is orders of magnitude higher than a transient vaccine. Scaling this isn't just a volume issue; it's a massive clinical trial hurdle. If the FDA requires long-term monitoring for oncogenic risk, the 'one-and-done' cost-benefit analysis against GLP-1s collapses entirely, regardless of payer willingness.
"Long-term safety tail risk and payer/regulatory hurdles for permanent genome edits could cap Verve-102's upside even if CV outcomes look durable."
Gemini's one-and-done thesis hinges on favorable CV outcomes and payer acceptance, but permanent liver base editing carries a long-tail safety burden regulators will scrutinize for decades. Even with durable LDL-C/ASCVD signals, long-term oncogenic and off-target risks could trigger post-approval surveillance costs, denial of coverage, and slower uptake than implied. Manufacturing isn't the only bottleneck—the regulatory tail risk and payer risk could erode the multiple from a 50B TAM to a fraction of that.
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Regulatory tail risk and payer acceptance for one-time edits